吉西他滨和长春瑞滨对比治疗老年晚期非小细胞肺癌临床研究  

Comparative study of navelbine and gemcitabine regimen in the treatment with advanced non-small cell lung cancer of the old age

作　　者：谢强[1] 陈群[1] 李育宏[1] 石琴[1] 陈雨燕[1] 林江平[1] 王成辉[1] 

机构地区：[1]福建医科大学教学医院福州肺科医院肿瘤科,350008

出　　处：《临床肺科杂志》2009年第1期50-52,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的对比观察长春瑞滨及吉西他滨在晚期老年非小细胞肺癌临床疗效及毒性反应。方法79例晚期老年非小细胞肺癌随机分为两组，长春瑞滨组39例，吉西他滨40例。结果所有被研究对象的症状均有不同程度的改善。长春瑞滨组有效率为36．84％，吉西他滨组有效率38．46％，两组间差异无显著性（P〉0．05），中位生存期（MST），吉西他滨组为9．6个月，长春瑞滨组为9．2个月。疾病缓解时间（DRT），吉西他滨组为4．3个月，长春瑞滨组为4．0个月，两组间差异无显著性。毒性反应：长春瑞滨组白细胞下降Ⅲ-Ⅳ度15．38％，吉西他滨组白细胞下降Ⅲ-Ⅳ度占15％，但吉西他滨组血小板Ⅲ-Ⅳ度下降有6例，占15％，明显高于长春瑞滨组（P〈0．05）。长春瑞滨组发生静脉炎10例，占25．64％，明显高于吉西他滨组（P〈0．05）。结论吉西他滨与长春瑞滨对晚期老年非小细胞肺癌的近期临床疗效相近，中位生存期及中位缓解期均相似，毒性反应总的较轻。吉西他滨单药或长春瑞滨单药方案均可作为治疗晚期老年非小细胞肺癌的一种安全、有效的化疗方案。Objective To evaluate and compare the effects and safety of navelbine and Gemcitabine regimen for patients of old age with advanced non-small cell lung cancer. Methods The 79 cases of patients of old age with advanced non-small cell lung were randomly divided into the navelbine regimen group and the gemcitabine regimen group. There were 39 patients in the navelbine regimen group, and 40 patients in the gemcitabine regimen group. Results The disease-related symptoms of all patients had improved more or less. The overall response rate was 38.46% for the GEM group and 36.84% for the NVB group. There was no significance （P〉0. 05） for the overall response rate between the groups. The median survival time （MST） was 9.6 months in the GEM group and 9. 2 months in the NVB group respectively. The disease median response time （DRT） was 4. 3 months in the GEM group and 4. 0 months in the NVB group respectively, MST and DRT were similar in the two groups （P 〉0. 05）. WHO grade Ⅲ-Ⅳ leucopenia occurred 15.38% in the NVB group, and grade Ⅲ-Ⅳ leucopenia occurred 15% in the GEM group. The grade Ⅲ-Ⅳ thrombocytopenia occurred was 15% in the GEM group, which was significantly higher than that in the NVB group. The frequence of phlebitis was 25.64% in the NVB group, which was also significantly higher than in the GEM group. Conclusion There were similar in the overall response rate, MST and DRT in the two groups. Toxicities were tolerable for GEM regimen and NVB regimen, which are very good and safe chemotherapeutic regimens for advanced NSCLC of the old age.

关 键 词：非小细胞肺癌 吉西他滨 长春瑞滨 老年 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R273.420.5[医药卫生—临床医学]